EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer

Ahmed A El-Shenawy iD, Mahmoud M A Elsayed iD, Gamal M K Atwa, Mohammed A S Abourehab iD, Mohamed S Mohamed, Mohammed M Ghoneim iD, Reda A Mahmoud, Shereen A Sabry iD, Walid Anwar iD, Mohamed El-Sherbiny iD, Yasser A Hassan, Amany Belal iD und 1 weitere

Pharmaceutics · 17.02.2023 · 15 (2) · 680

DOI: 10.3390/pharmaceutics15020680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 17.02.2023. Verfasst von Ahmed A El-Shenawy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umm al-Qura University, Research & Innovation, Ministry of Education in Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gefitinib (GFT) is a tyrosine kinase inhibitor drug used as a first-line treatment for patients with advanced or metastatic non-small cell lung, colon, and breast cancer. GFT exhibits low solubility and hence low oral bioavailability, which restricts its clinical application. One of the most important trends in overcoming such problems is the use of a vesicular system. Cubosomes are considered one of the most important vesicular systems used to improve solubility and oral bioavailability. In this study, GFT cubosomal nanoparticles (GFT-CNPs) were prepared by the emulsification method. The selected formulation variables were analyzed and optimized by full factorial design and response surface methodology. Drug entrapment efficiency (EE%), transmission electron microscopy, particle size, polydispersity index, in vitro release and its kinetics, and the effect of storage studies were estimated. The chosen GFT-CNPs were subjected to further investigations as gene expression levels of tissue inhibitors of metalloproteinases-1 (TIMP-1) and matrix metalloproteinases-7 (MMP-7), colon biomarkers, and histopathological examination of colon tissues. The prepared GFT-CNPs were semi-cubic in shape, with high EE%, smaller vesicle size, and higher zeta potential values. The in vivo data showed a significant decrease in the serum level of embryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and gene expression level of TIMP-1 and MMP-7. Histopathological examination showed enhancement in cancer tissue and highly decreased focal infiltration in the lamina propria after treatment with GFT-CNPs.

Schlagwörter

Stichwörter der Autor:innen

colon cancergefitinibgene expressionhistopathological examinationnanoparticlesnanosized cubosomes

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt.
  • Department of Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.
  • Department of Biochemistry, Faculty of Pharmacy, Port Said University, Port Said 42515, Egypt.
  • Department of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
  • Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.
  • Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.

ORCID-Profile: Ahmed A El-Shenawy, Mahmoud M A Elsayed, Mohammed A S Abourehab, Mohammed M Ghoneim, Shereen A Sabry, Walid Anwar, Mohamed El-Sherbiny, Amany Belal, Abd El Hakim Ramadan

Förderung

  • Umm al-Qura University
  • Research & Innovation, Ministry of Education in Saudi Arabia

Zitieren

APA

El-Shenawy, A. A., Elsayed, M. M. A., Atwa, G. M. K., Abourehab, M. A. S., Mohamed, M. S., Ghoneim, M. M., Mahmoud, R. A., Sabry, S. A., Anwar, W., El-Sherbiny, M., Hassan, Y. A., Belal, A., & Ramadan, A. E. H. (2023). Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics, 15(2), 680. https://doi.org/10.3390/pharmaceutics15020680

Vancouver

El-Shenawy AA, Elsayed MMA, Atwa GMK, Abourehab MAS, Mohamed MS, Ghoneim MM, et al. Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer. Pharmaceutics. 2023;15(2):680. doi:10.3390/pharmaceutics15020680

BibTeX
@article{ElShenawy2023,
  author = {El-Shenawy, Ahmed A and Elsayed, Mahmoud M A and Atwa, Gamal M K and Abourehab, Mohammed A S and Mohamed, Mohamed S and Ghoneim, Mohammed M and Mahmoud, Reda A and Sabry, Shereen A and Anwar, Walid and El-Sherbiny, Mohamed and Hassan, Yasser A and Belal, Amany and Ramadan, Abd El Hakim},
  title = {Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {680},
  doi = {10.3390/pharmaceutics15020680}
}
Kostenlos starten →